Restatement and prospectives of ergot alkaloids in clinical neurology and psychiatry

A. Agnoli, S. Ruggieri, M. Casacchia

Research output: Contribution to journalArticle

Abstract

The pharmacological action of the ergot alkaloids on the brain, except for the well-known hallucinogenic effects, has never been well understood. If we exclude the documented a-adrenolytic action and the central nervous system depression, nothing has been described with certainty. However, therapeutically, a pharmacologic action could be documented both in the elderly and in chronic cerebrovascular disorders, such as reduction in subjective symptomatology and overall improvement in the autonomy. This was generally associated with a psychotonic action. Considering these results for many years, researchers have been attempting to demonstrate the pharmacological action of ergot alkaloids on the cerebral circulation and metabolism. It has, therefore, been wished to demonstrate the effect on the cerebral blood flow, the metabolism and the EEG. The possibility of a psychopharmacological effect, whose mode of action could not be evidenced evaluating parameters using such coarse techniques, has been demonstrated. In our view, the new dimension shown by bromocriptine is in accordance with these considerations. Therefore, our presentation should be restricted to the results and the prospectives opened by bromocriptine in neuropsychiatry. We shall report our personal results obtained in parkinsonism, degenerative chorea and the depressive syndromes. Studies in progress in the elderly and in epilepsy will also be reported.

Original languageEnglish
Pages (from-to)174-188
Number of pages15
JournalPharmacology
Volume16
DOIs
Publication statusPublished - 1978

Fingerprint

Cerebrovascular Circulation
Ergot Alkaloids
Bromocriptine
Neurology
Psychiatry
Pharmacology
Neuropsychiatry
Pharmacologic Actions
Cerebrovascular Disorders
Chorea
Adrenergic Antagonists
Parkinsonian Disorders
Depressive Disorder
Electroencephalography
Epilepsy
Central Nervous System
Research Personnel
Depression
Brain

Keywords

  • Chorea
  • Depression
  • Ergot alkaloids
  • Extrapyramidal disorders
  • Neuropharmacology
  • Parkinsonism

ASJC Scopus subject areas

  • Pharmacology

Cite this

Restatement and prospectives of ergot alkaloids in clinical neurology and psychiatry. / Agnoli, A.; Ruggieri, S.; Casacchia, M.

In: Pharmacology, Vol. 16, 1978, p. 174-188.

Research output: Contribution to journalArticle

Agnoli, A. ; Ruggieri, S. ; Casacchia, M. / Restatement and prospectives of ergot alkaloids in clinical neurology and psychiatry. In: Pharmacology. 1978 ; Vol. 16. pp. 174-188.
@article{393f1ae42ccb48d09ee48204df7dfc35,
title = "Restatement and prospectives of ergot alkaloids in clinical neurology and psychiatry",
abstract = "The pharmacological action of the ergot alkaloids on the brain, except for the well-known hallucinogenic effects, has never been well understood. If we exclude the documented a-adrenolytic action and the central nervous system depression, nothing has been described with certainty. However, therapeutically, a pharmacologic action could be documented both in the elderly and in chronic cerebrovascular disorders, such as reduction in subjective symptomatology and overall improvement in the autonomy. This was generally associated with a psychotonic action. Considering these results for many years, researchers have been attempting to demonstrate the pharmacological action of ergot alkaloids on the cerebral circulation and metabolism. It has, therefore, been wished to demonstrate the effect on the cerebral blood flow, the metabolism and the EEG. The possibility of a psychopharmacological effect, whose mode of action could not be evidenced evaluating parameters using such coarse techniques, has been demonstrated. In our view, the new dimension shown by bromocriptine is in accordance with these considerations. Therefore, our presentation should be restricted to the results and the prospectives opened by bromocriptine in neuropsychiatry. We shall report our personal results obtained in parkinsonism, degenerative chorea and the depressive syndromes. Studies in progress in the elderly and in epilepsy will also be reported.",
keywords = "Chorea, Depression, Ergot alkaloids, Extrapyramidal disorders, Neuropharmacology, Parkinsonism",
author = "A. Agnoli and S. Ruggieri and M. Casacchia",
year = "1978",
doi = "10.1159/000136818",
language = "English",
volume = "16",
pages = "174--188",
journal = "Pharmacology",
issn = "0031-7012",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Restatement and prospectives of ergot alkaloids in clinical neurology and psychiatry

AU - Agnoli, A.

AU - Ruggieri, S.

AU - Casacchia, M.

PY - 1978

Y1 - 1978

N2 - The pharmacological action of the ergot alkaloids on the brain, except for the well-known hallucinogenic effects, has never been well understood. If we exclude the documented a-adrenolytic action and the central nervous system depression, nothing has been described with certainty. However, therapeutically, a pharmacologic action could be documented both in the elderly and in chronic cerebrovascular disorders, such as reduction in subjective symptomatology and overall improvement in the autonomy. This was generally associated with a psychotonic action. Considering these results for many years, researchers have been attempting to demonstrate the pharmacological action of ergot alkaloids on the cerebral circulation and metabolism. It has, therefore, been wished to demonstrate the effect on the cerebral blood flow, the metabolism and the EEG. The possibility of a psychopharmacological effect, whose mode of action could not be evidenced evaluating parameters using such coarse techniques, has been demonstrated. In our view, the new dimension shown by bromocriptine is in accordance with these considerations. Therefore, our presentation should be restricted to the results and the prospectives opened by bromocriptine in neuropsychiatry. We shall report our personal results obtained in parkinsonism, degenerative chorea and the depressive syndromes. Studies in progress in the elderly and in epilepsy will also be reported.

AB - The pharmacological action of the ergot alkaloids on the brain, except for the well-known hallucinogenic effects, has never been well understood. If we exclude the documented a-adrenolytic action and the central nervous system depression, nothing has been described with certainty. However, therapeutically, a pharmacologic action could be documented both in the elderly and in chronic cerebrovascular disorders, such as reduction in subjective symptomatology and overall improvement in the autonomy. This was generally associated with a psychotonic action. Considering these results for many years, researchers have been attempting to demonstrate the pharmacological action of ergot alkaloids on the cerebral circulation and metabolism. It has, therefore, been wished to demonstrate the effect on the cerebral blood flow, the metabolism and the EEG. The possibility of a psychopharmacological effect, whose mode of action could not be evidenced evaluating parameters using such coarse techniques, has been demonstrated. In our view, the new dimension shown by bromocriptine is in accordance with these considerations. Therefore, our presentation should be restricted to the results and the prospectives opened by bromocriptine in neuropsychiatry. We shall report our personal results obtained in parkinsonism, degenerative chorea and the depressive syndromes. Studies in progress in the elderly and in epilepsy will also be reported.

KW - Chorea

KW - Depression

KW - Ergot alkaloids

KW - Extrapyramidal disorders

KW - Neuropharmacology

KW - Parkinsonism

UR - http://www.scopus.com/inward/record.url?scp=0017798430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017798430&partnerID=8YFLogxK

U2 - 10.1159/000136818

DO - 10.1159/000136818

M3 - Article

C2 - 347463

AN - SCOPUS:0017798430

VL - 16

SP - 174

EP - 188

JO - Pharmacology

JF - Pharmacology

SN - 0031-7012

ER -